-
Product Insights
Neurogenic Locus Notch Homolog Protein 1 – Drugs In Development, 2023
Global Markets Direct’s Neurogenic Locus Notch Homolog Protein 1 provides in depth analysis on Neurogenic Locus Notch Homolog Protein 1 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved...
-
Track & Monitor
NewArtificial Intelligence in Retail: Planogram modelling
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the retail industry’s Planogram modelling segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tilpisertib Fosmecarbil in Ulcerative Colitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tilpisertib Fosmecarbil in Ulcerative Colitis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tilpisertib Fosmecarbil in Ulcerative Colitis Drug Details: Tilpisertib fosmecarbil (GS-5290)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LBPEC-01 in Escherichia coli Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LBPEC-01 in Escherichia coli Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LBPEC-01 in Escherichia coli Infections Drug Details: LBPEC-01 is under development...
-
Product Insights
Urinary Tract Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Urinary Tract Infections - Drugs In Development, 2023’, provides an overview of the Urinary Tract Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Urinary Tract Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EDIT-301 in Sickle Cell Disease
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. EDIT-301 in Sickle Cell Disease Drug Details: EDIT-301 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EDIT-301 in Beta Thalassaemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EDIT-301 in Beta Thalassaemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.EDIT-301 in Beta Thalassaemia Drug Details:EDIT-301 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LBPEC-01 in Urinary Tract Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LBPEC-01 in Urinary Tract Infections report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LBPEC-01 in Urinary Tract Infections Drug Details: LBPEC-01 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RPTR-147 in Metastatic Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RPTR-147 in Metastatic Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.RPTR-147 in Metastatic Ovarian Cancer Drug Details: RPTR-147 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Roneparstat in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Roneparstat in Refractory Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Roneparstat in Refractory Multiple Myeloma Drug Details: Roneparstat (SST-0001) is...